Get the Stockscreener App
332.92
2.98%
9.63
After Hours:
332.91
-0.010
-0.00%
Praxis Precision Medicines Inc stock is traded at $332.92, with a volume of 419.25K.
It is up +2.98% in the last 24 hours and up +20.74% over the past month.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.
See More
Previous Close:
$323.29
Open:
$323.99
24h Volume:
419.25K
Relative Volume:
0.59
Market Cap:
$9.23B
Revenue:
$1.77M
Net Income/Loss:
$-123.74M
P/E Ratio:
-36.31
EPS:
-9.17
Net Cash Flow:
$-95.21M
1W Performance:
+8.93%
1M Performance:
+20.74%
6M Performance:
+587.00%
1Y Performance:
+289.84%
1-Day Range:
$317.82
$335.75
1-Week Range:
$302.00
$335.75
52-Week Range:
$26.70
$335.75
Praxis Precision Medicines Inc Stock (PRAX) Company Profile
Name
Praxis Precision Medicines Inc
Sector
Industry
Phone
617-300-8460
Address
99 HIGH STREET, 30TH FLOOR, BOSTON
Compare PRAX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PRAX
Praxis Precision Medicines Inc
|
332.92 | 8.97B | 1.77M | -123.74M | -95.21M | -9.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Praxis Precision Medicines Inc Stock (PRAX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-02-26 | Initiated | Wells Fargo | Equal Weight |
| Dec-15-25 | Reiterated | Oppenheimer | Outperform |
| Nov-19-25 | Initiated | BTIG Research | Buy |
| Jun-02-25 | Resumed | Oppenheimer | Outperform |
| May-07-25 | Initiated | Chardan Capital Markets | Buy |
| Mar-03-25 | Reiterated | H.C. Wainwright | Buy |
| Feb-11-25 | Initiated | Deutsche Bank | Buy |
| Aug-05-24 | Initiated | Oppenheimer | Outperform |
| Jun-24-24 | Initiated | Needham | Buy |
| Jun-18-24 | Initiated | Guggenheim | Buy |
| May-01-24 | Initiated | Robert W. Baird | Outperform |
| Sep-19-23 | Initiated | Truist | Buy |
| Jun-06-22 | Downgrade | Wedbush | Outperform → Neutral |
| Dec-16-21 | Initiated | H.C. Wainwright | Buy |
| Aug-26-21 | Initiated | BofA Securities | Buy |
| Apr-26-21 | Initiated | William Blair | Outperform |
| Nov-11-20 | Initiated | Wedbush | Outperform |
| Nov-10-20 | Initiated | Cowen | Outperform |
| Nov-10-20 | Initiated | Evercore ISI | Outperform |
| Nov-10-20 | Initiated | Piper Sandler | Overweight |
View All
Praxis Precision Medicines Inc Stock (PRAX) Latest News
Praxis Precision Medicines stock hits 52-week high at 327.0 USD - Investing.com Nigeria
PRAX: Two NDAs set for mid-February aim to address major CNS markets with strong launch plans - TradingView
Arizona State Retirement System Purchases Shares of 5,417 Praxis Precision Medicines, Inc. $PRAX - MarketBeat
Will Praxis Precision Medicines Inc. stock attract more institutional investors2025 Price Targets & Real-Time Stock Price Movement Reports - mfd.ru
Guggenheim Raises Price Target for Praxis Precision Medicines (PRAX) | PRAX Stock News - GuruFocus
Guggenheim raises Praxis Precision Medicines stock price target on essential tremor opportunity - Investing.com India
Praxis Precision Medicines (NASDAQ:PRAX) Hits New 1-Year HighHere's Why - MarketBeat
Praxis Precision Medicines to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 19, 2026, and Participate in Upcoming Investor Conferences - Investing News Network
Praxis Precision Medicines to Report Fourth Quarter and - GlobeNewswire
Praxis Precision Medicines stock hits 52-week high at 327.0 USD By Investing.com - Investing.com South Africa
A Look At Praxis Precision Medicines (PRAX) Valuation As Analysts Reaffirm Bullish CNS Pipeline Views - Yahoo Finance
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Avoiding Lag: Real-Time Signals in (PRAX) Movement - Stock Traders Daily
Certain Stock Options of Praxis Precision Medicines, Inc. are subject to a Lock-Up Agreement Ending on 6-FEB-2026. - marketscreener.com
Certain Common Stock of Praxis Precision Medicines, Inc. are subject to a Lock-Up Agreement Ending on 6-FEB-2026. - marketscreener.com
Is Praxis Precision Medicines (PRAX) Now Pricing In Recent Pipeline Progress And Volatile Share Gains - Sahm
Praxis Precision Medicines (PRAX) Price Target Increased by 26.75% to 597.99 - Nasdaq
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Praxis Precision Medicines, Inc. announces inducement grants under Nasdaq Listing Rule - marketscreener.com
Needham Raises Price Target for Praxis Precision Medicine (PRAX) - GuruFocus
Needham & Company LLC Boosts Praxis Precision Medicines (NASDAQ:PRAX) Price Target to $510.00 - MarketBeat
Why Praxis Precision Medicines (PRAX) Is Up 5.1% After Dual NDA Plans And Data Platform Expansion - Sahm
Analysts Are Bullish on These Healthcare Stocks: Regeneron (REGN), Praxis Precision Medicines (PRAX) - The Globe and Mail
Wells Fargo Initiates Coverage of Praxis Precision Medicines (PRAX) with Equal-Weight Recommendation - Nasdaq
SEQSTER Announces Expanded Partnership with Praxis Precision Medicines to Accelerate Clinical Trials in CNS Disorders - 01net
Wells Fargo Initiates Coverage on PRAX with Equal-Weight Rating - GuruFocus
Wells Fargo Initiates Coverage on Praxis Precision Medicines With Equal Weight Rating, $282 Price Target - marketscreener.com
Praxis Precision Medicines (NASDAQ:PRAX) Now Covered by Analysts at Wells Fargo & Company - MarketBeat
A Look At Praxis Precision Medicines (PRAX) Valuation After Breakthrough NDA Plans And Rising Investor Interest - Sahm
Aug Chart Watch: Is Praxis Precision Medicines Inc stock a smart retirement pickAnalyst Upgrade & Safe Capital Growth Tips - baoquankhu1.vn
3,846 Shares in Praxis Precision Medicines, Inc. $PRAX Acquired by Coastal Bridge Advisors LLC - MarketBeat
Praxis Precision Medicines, Inc (PRAX) Stock Analysis: Exploring a 63% Upside in the Biotech Sector - DirectorsTalk Interviews
PRAX: HC Wainwright & Co. Raises Price Target and Maintains Buy Rating | PRAX Stock News - GuruFocus
H.C. Wainwright raises Praxis Precision Medicines stock price target to $1,245 - Investing.com Nigeria
Y Intercept Hong Kong Ltd Makes New $1.71 Million Investment in Praxis Precision Medicines, Inc. $PRAX - MarketBeat
Praxis Precision Medicines plans two NDA submissions by mid-February - Investing.com Nigeria
Phoenix Financial Ltd. Makes New Investment in Praxis Precision Medicines, Inc. $PRAX - MarketBeat
Piper Sandler raises Praxis Precision Medicines stock price target to $1,200 - Investing.com Canada
Is Praxis Precision Medicines Inc part of any major indexTrade Analysis Report & Daily Market Momentum Tracking - baoquankhu1.vn
Piper Sandler Raises PRAX Price Target to $1,200, Maintains Overweight Rating | PRAX Stock News - GuruFocus
Discipline and Rules-Based Execution in PRAX Response - Stock Traders Daily
A Look At Praxis Precision Medicines (PRAX) Valuation As Late Stage Epilepsy Plans Move Toward FDA Filings - Sahm
Should Praxis Precision Medicines’ (PRAX) New Clinical Strategy Chief Reshape Its Long-Term Epilepsy Investment Story? - Sahm
Piper Sandler Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $450 - 富途牛牛
Piper Sandler reiterates Overweight rating on Praxis Precision Medicines stock - Investing.com
SG Americas Securities LLC Invests $715,000 in Praxis Precision Medicines, Inc. $PRAX - MarketBeat
PRAX Stock Price, Forecast & Analysis | PRAXIS PRECISION MEDICINES I (NASDAQ:PRAX) - Chartmill
Praxis speeds up R&D plans for seizure therapy after FDA feedback - MSN
Analysts Offer Insights on Healthcare Companies: Solventum Corporation (SOLV) and Praxis Precision Medicines (PRAX) - The Globe and Mail
Nisa Investment Advisors LLC Has $378,000 Stake in Praxis Precision Medicines, Inc. $PRAX - MarketBeat
Praxis Precision Medicines stock hits 52-week high at $318.24 By Investing.com - Investing.com Nigeria
Praxis Precision Medicines Inc Stock (PRAX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):